US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by C4 Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics to Participate in Upcoming Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC RHHBY
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics to Participate in Upcoming March Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics to Participate in Upcoming March Investor Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
News headline image
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
From C4 Therapeutics, Inc.
Via GlobeNewswire
Tickers CCCC
< Previous 1 2 Next >